125 related articles for article (PubMed ID: 10155580)
1. The National Health Service pharmaceuticals market. Recent and prospective reforms.
Green DG
Pharmacoeconomics; 1994; 6 Suppl 1():11-4. PubMed ID: 10155580
[No Abstract] [Full Text] [Related]
2. Drug costs. Compound interests.
Stewart A
Health Serv J; 1994 Dec; 104(5431):30-1. PubMed ID: 10139796
[No Abstract] [Full Text] [Related]
3. The United Kingdom National Health Service reforms: where are we now?
Drummond M
Aust Health Rev; 1995; 18(1):28-42. PubMed ID: 10141962
[TBL] [Abstract][Full Text] [Related]
4. Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?
Freemantle N
Health Policy; 1999 Mar; 46(3):255-65. PubMed ID: 10351671
[TBL] [Abstract][Full Text] [Related]
5. Policy and ideology: the politics of post-reform health policy in the United Kingdom.
Fierlbeck K
Int J Health Serv; 1996; 26(3):529-46. PubMed ID: 8840201
[TBL] [Abstract][Full Text] [Related]
6. Introducing a market to the United Kingdom's National Health Service.
Maynard A; Bloor K
N Engl J Med; 1996 Feb; 334(9):604-8. PubMed ID: 8569843
[No Abstract] [Full Text] [Related]
7. Evaluation of pharmaceutical innovation: challenges and opportunities arising from the reforms to the national health service in the United Kingdom.
St Leger S; Rowsell K; Standing V; Haycox A
Pharmacoeconomics; 1992 May; 1(5):306-11. PubMed ID: 10146995
[No Abstract] [Full Text] [Related]
8. Dueling spending projections. OMB pins $534 billion price tag on Rx benefit.
Tieman J
Mod Healthc; 2004 Feb; 34(5):10-1. PubMed ID: 14974299
[No Abstract] [Full Text] [Related]
9. Cardiovascular disease prevention and the NHS reforms.
Mant J; Street S
J Cardiovasc Risk; 1996 Oct; 3(5):435-9. PubMed ID: 9048258
[TBL] [Abstract][Full Text] [Related]
10. The recent health reforms in the United Kingdom: some tentative observations on their impact on nurses and nursing in hospitals.
Bradshaw PL
J Adv Nurs; 1995 May; 21(5):975-9. PubMed ID: 7602007
[TBL] [Abstract][Full Text] [Related]
11. Present dangers and future threats: some perverse incentives in the NHS reforms.
Paton C
BMJ; 1995 May; 310(6989):1245-8. PubMed ID: 7767197
[TBL] [Abstract][Full Text] [Related]
12. Focus: National Health Service.
Health Estate J; 1997 Feb; 51(1):4-6. PubMed ID: 10165173
[No Abstract] [Full Text] [Related]
13. Pharmaceutical expenditure in Sweden.
Henriksson F; Hjortsberg C; Rehnberg C
Health Policy; 1999 May; 47(2):125-44. PubMed ID: 10538288
[TBL] [Abstract][Full Text] [Related]
14. Down on their uppers.
Moore A
Health Serv J; 2003 Mar; 113(5848):14-5. PubMed ID: 12718202
[No Abstract] [Full Text] [Related]
15. "Reforms will make cash tills ring and leave us all the poorer".
Adams G
Nurs Times; 2011 Feb 8-14; 107(5):7. PubMed ID: 21473307
[No Abstract] [Full Text] [Related]
16. Competition in the British National Health Service.
Bayne N
Leadersh Health Serv; 1994; 3(4):5-9. PubMed ID: 10136720
[TBL] [Abstract][Full Text] [Related]
17. Value-Based Pricing and State Reform of Prescription Drug Costs.
Hwang TJ; Kesselheim AS; Sarpatwari A
JAMA; 2017 Aug; 318(7):609-610. PubMed ID: 28692713
[No Abstract] [Full Text] [Related]
18. Moving toward managed care: the United Kingdom National Health Service reforms.
Bach S
Health Care Manag; 1995 Oct; 2(1):151-60. PubMed ID: 10165629
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical expenditure in Spain: cost and control.
Lopez Bastida J; Mossialos E
Int J Health Serv; 2000; 30(3):597-616. PubMed ID: 11109184
[TBL] [Abstract][Full Text] [Related]
20. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
Henry DA; Hill SR; Harris A
JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
[No Abstract] [Full Text] [Related]
[Next] [New Search]
